BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2980713)

  • 1. Light microscopical morphometry of prolactin secreting adenomas under treatment with dopamine agonists.
    Hamester U; Saeger W; Lüdecke DK
    Histol Histopathol; 1987 Apr; 2(2):135-42. PubMed ID: 2980713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Necroses of prolactin-secreting pituitary adenomas under treatment with dopamine agonists: light microscopical and morphometric studies.
    Hallenga B; Saeger W; Lüdecke DK
    Exp Clin Endocrinol; 1988 Sep; 92(1):59-68. PubMed ID: 2906615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrastructural morphometry of prolactin secreting adenomas treated with dopamine agonists.
    Schottke H; Saeger W; Lüdecke DK; Caselitz J
    Pathol Res Pract; 1986 Jun; 181(3):280-90. PubMed ID: 3748874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas.
    Jones TH; Figueroa CD; Smith CM; Bhoola KD
    Agents Actions Suppl; 1992; 38 ( Pt 2)():175-82. PubMed ID: 1462825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists.
    Kontogeorgos G; Horvath E; Kovacs K; Coire C; Lloyd RV; Scheithauer BW; Smyth HS
    Acta Neuropathol; 2006 Jan; 111(1):46-52. PubMed ID: 16328513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Light and electron microscopical morphometry of pituitary adenomas in hyperprolactinemia.
    Saeger W; Mohr K; Caselitz J; Lüdecke DK
    Pathol Res Pract; 1986 Oct; 181(5):544-50. PubMed ID: 3024139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of prolactinoma with a new dopamine agonist].
    Svoboda T; Luger A; Knosp E; Geyer G
    Dtsch Med Wochenschr; 1991 Aug; 116(33):1224-7. PubMed ID: 1678695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactin-secreting adenomas. A light and electron microscopical study.
    Robert F; Hardy J
    Arch Pathol; 1975 Dec; 99(12):625-33. PubMed ID: 1239266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Giant invasive prolactinoma: a case report and review of nine further cases.
    Davis JR; Sheppard MC; Heath DA
    Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine.
    Adler I; Barsi P; Czirják S; Varga I; Gergics P; Jakab C; Rácz K
    Gynecol Endocrinol; 2005 Jun; 20(6):317-21. PubMed ID: 16019380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
    Teramoto A; Sanno N; Tahara S; Osamura YR
    Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Morphological changes in prolactinoma induced by bromocriptine treatment].
    Scanarini M
    Minerva Endocrinol; 1990; 15(1):13-5. PubMed ID: 2274009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B; Nesher Y; Barziliai S
    J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of treatment for male prolactinomas].
    Iwai Y; Yamanaka K; Ishiguro T; Morikawa T; Matsuzaka Y; Komiyama M; Yasui T
    No Shinkei Geka; 2002 Dec; 30(12):1285-92. PubMed ID: 12491580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of hypophyseal prolactin-secreting macroadenomas].
    Candrina R; Tosoni M
    Recenti Prog Med; 1989 Sep; 80(9):471-3. PubMed ID: 2595078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
    Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
    Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.
    Ma W; Ikeda H; Yoshimoto T
    Cancer; 2002 Jul; 95(2):258-66. PubMed ID: 12124824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrinological outcome following first time transsphenoidal surgery for GH-, ACTH-, and PRL-secreting pituitary adenomas.
    Kristof RA; Schramm J; Redel L; Neuloh G; Wichers M; Klingmüller D
    Acta Neurochir (Wien); 2002 Jun; 144(6):555-61; discussion 561. PubMed ID: 12111488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of extensively invasive (giant) prolactinomas with bromocriptine.
    Grebe SK; Delahunt JW; Feek CM
    N Z Med J; 1992 Apr; 105(931):129-31. PubMed ID: 1560924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.
    Karavitaki N; Thanabalasingham G; Shore HC; Trifanescu R; Ansorge O; Meston N; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):524-9. PubMed ID: 16984247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.